Design Therapeutics, Inc. Deferred Tax Liabilities, Net
Design Therapeutics, Inc. (DSGN) had Deferred Tax Liabilities, Net of $546.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net
us-gaap:DeferredTaxLiabilities · last filed 2026-03-09
- 2025-12-31: Deferred Tax Liabilities, Net $546.00K.
- 2024-12-31: Deferred Tax Liabilities, Net $836.00K.
- 2023-12-31: Deferred Tax Liabilities, Net $975.00K.
- 2022-12-31: Deferred Tax Liabilities, Net $1.17M.
| Period end | Deferred Tax Liabilities, Net |
|---|---|
| 2025-12-31 | $546.00K 10-K · filed 2026-03-09 |
| 2024-12-31 | $836.00K 10-K · filed 2026-03-09 |
| 2023-12-31 | $975.00K 10-K · filed 2025-03-10 |
| 2022-12-31 | $1.17M 10-K · filed 2024-03-19 |
| 2021-12-31 | $759.00K 10-K · filed 2023-03-14 |
| 2020-12-31 | $33.00K 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |